Northwestern Mutual Investment Management Company’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-2,024
Closed -$545K 907
2021
Q3
$545K Hold
2,024
0.01% 759
2021
Q2
$521K Sell
2,024
-2
-0.1% -$554 0.01% 785
2021
Q1
$608K Sell
2,026
-2,086
-51% -$649K 0.01% 709
2020
Q4
$1.05M Sell
4,112
-17
-0.4% -$4.39K 0.01% 610
2020
Q3
$1.43M Hold
4,129
0.02% 376
2020
Q2
$1.43M Buy
4,129
+53
+1% +$16.5K 0.02% 377
2020
Q1
$1.09M Buy
4,076
+726
+22% +$225K 0.02% 399
2019
Q4
$1.08M Buy
3,350
+2,905
+653% +$842K 0.02% 465
2019
Q3
$122K Buy
445
+4
+0.9% +$1.47K ﹤0.01% 917
2019
Q2
$235K Sell
441
-1,323
-75% -$663K 0.01% 885
2019
Q1
$889K Buy
1,764
+27
+2% +$16K 0.02% 607
2018
Q4
$857K Sell
1,737
-275
-14% -$166K 0.01% 601
2018
Q3
$1.84M Sell
2,012
-45
-2% -$38.4K 0.03% 458
2018
Q2
$1.51M Buy
2,057
+104
+5% +$120K 0.02% 515
2018
Q1
$3.11M Buy
+1,953
New +$2.52M 0.05% 312

Other funds holding NKTR

Northwestern Mutual Investment Management Company's NKTR Position: Q4 2021 in Review

Northwestern Mutual Investment Management Company sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 2,024 shares — an estimated $545K sold.

Northwestern Mutual Investment Management Company first reported a position in NKTR in Q1 2018 and held it in 15 quarters. The position peaked at $3.11M in Q1 2018. 241 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Northwestern Mutual Investment Management Company reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Northwestern Mutual Investment Management Company sold 2,024 Nektar Therapeutics shares in Q4 2021, an estimated $545K.
  • Northwestern Mutual Investment Management Company first reported a position in Nektar Therapeutics in Q1 2018 and held it in 15 quarters.
  • Northwestern Mutual Investment Management Company's Nektar Therapeutics position peaked at $3.11M in Q1 2018.
  • 241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Northwestern Mutual Investment Management Company's 13F filing for Q4 2021, filed 3 Feb 2022.